Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mark J. Ginski is active.

Publication


Featured researches published by Mark J. Ginski.


International Journal of Pharmaceutics | 1999

Prediction of dissolution–absorption relationships from a dissolution/Caco-2 system

Mark J. Ginski; James E. Polli

While the analysis of in vitro dissolution-in vivo absorption relationships from oral solid dosage forms provides biopharmaceutical insight and regulatory benefit, no well developed method exists to predict dissolution-absorption relationships a priori to human studies. The objective was to develop an integrated dissolution/Caco-2 system to predict dissolution-absorption relationships, and hence the contributions of dissolution and intestinal permeation to overall drug absorption for fast and slow formulations of piroxicam, metoprolol, and ranitidine. Dissolution studies were conducted on fast and slow dissolving immediate-release formulations of piroxicam, metoprolol tartrate, and ranitidine HCl. Dissolution samples were treated with concentrated buffers to render them suitable (i.e., isotonic and neutral pH) for Caco-2 monolayer permeation studies. The dissolution/Caco-2 system yielded a predicted dissolution-absorption relationship for each formulation which matched the observed relationship from clinical studies. The dissolution/Caco-2 systems prediction of dissolution or permeation rate-limited absorption also agreed with the clinical results. For example, the dissolution/Caco-2 system successfully predicted the slow piroxicam formulation to be dissolution rate-limited, and the fast piroxicam formulation to be permeation rate-limited. Moreover, the system predicted this change from dissolution rate-limited absorption for slow piroxicam to permeation rate-limited absorption for fast piroxicam, in spite of piroxicams high permeability and low solubility. The dissolution/Caco-2 system may prove to be a valuable tool in formulation development. Broader evaluation of such a system is warranted.


International Journal of Pharmaceutics | 2009

Mechanism of action of ZOT-derived peptide AT-1002, a tight junction regulator and absorption enhancer.

Shobha Gopalakrishnan; Niranjan B. Pandey; Amir P. Tamiz; John Vere; Rosa Carrasco; Robert Somerville; Amit Tripathi; Mark J. Ginski; Blake Paterson; Sefik S. Alkan

Tight junctions (TJs) are intercellular structures that control paracellular permeability and epithelial polarity. It is now accepted that TJs are highly dynamic structures that are regulated in response to exogenous and endogenous stimuli. Here, we provide details on the mechanism of action of AT-1002, the active domain of Vibrio choleraes second toxin, zonula occludens toxin (ZOT). AT-1002, a hexamer peptide, caused the redistribution of ZO-1 away from cell junctions as seen by fluorescence microscopy. AT-1002 also activated src and mitogen activated protein (MAP) kinase pathways, increased ZO-1 tyrosine phosphorylation, and rearrangement of actin filaments. Functionally, AT-1002 caused a reversible reduction in transepithelial electrical resistance (TEER) and an increase in lucifer yellow permeability in Caco-2 cell monolayers. In vivo, co-administration of salmon calcitonin with 1 mg of AT-1002 resulted in a 5.2-fold increase in AUC over the control group. Our findings provide a mechanistic explanation for AT-1002-induced tight junction disassembly, and demonstrate that AT-1002 can be used for delivery of other agents in vivo.


Pharmaceutical Research | 1998

Human Drug Absorption Kinetics and Comparison to Caco-2 Monolayer Permeabilities

James E. Polli; Mark J. Ginski


Archive | 2007

Formulations for a tight junction effector

Blake Paterson; Mark J. Ginski


Archive | 2013

Method for treating celiac disease

Blake Paterson; Mark J. Ginski


Archive | 2011

Antitussive compositions comprising memantine

Blake Paterson; Mark J. Ginski; Brendan J. Canning


Archive | 2013

Compositions et méthodes destinées à traiter la toux

Mark J. Ginski; Blake Paterson; Reza Mazhari; Djelila Mezaache


Archive | 2013

COMPOSITIONS AND METHODS FOR TREATING COUGH

Mark J. Ginski; Blake Paterson; Reza Mazhari; Djelila Mezaache


Archive | 2011

Compositions antitussives comprenant de la mémantine

Blake Paterson; Mark J. Ginski; Brendan J. Canning


Archive | 2007

Formulierungen für tight-junction-effektor

Blake Paterson; Mark J. Ginski

Collaboration


Dive into the Mark J. Ginski's collaboration.

Top Co-Authors

Avatar

Blake Paterson

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Reza Mazhari

Johns Hopkins University

View shared research outputs
Top Co-Authors

Avatar

Amir P. Tamiz

Georgetown University Medical Center

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge